JP2010504994A5 - - Google Patents

Download PDF

Info

Publication number
JP2010504994A5
JP2010504994A5 JP2009530553A JP2009530553A JP2010504994A5 JP 2010504994 A5 JP2010504994 A5 JP 2010504994A5 JP 2009530553 A JP2009530553 A JP 2009530553A JP 2009530553 A JP2009530553 A JP 2009530553A JP 2010504994 A5 JP2010504994 A5 JP 2010504994A5
Authority
JP
Japan
Prior art keywords
compound
effective amount
hydrogen
formula
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009530553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010504994A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/079381 external-priority patent/WO2008039751A2/en
Publication of JP2010504994A publication Critical patent/JP2010504994A/ja
Publication of JP2010504994A5 publication Critical patent/JP2010504994A5/ja
Pending legal-status Critical Current

Links

JP2009530553A 2006-09-28 2007-09-25 2−メチレン−(20s,25s)−19,27−ジノル−(22e)−ビタミンd類縁体 Pending JP2010504994A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84880506P 2006-09-28 2006-09-28
PCT/US2007/079381 WO2008039751A2 (en) 2006-09-28 2007-09-25 2-methylene-(20s,25s)-19,27-dinor-(22e)-vitamin d analogs

Publications (2)

Publication Number Publication Date
JP2010504994A JP2010504994A (ja) 2010-02-18
JP2010504994A5 true JP2010504994A5 (cg-RX-API-DMAC7.html) 2010-10-21

Family

ID=39172159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009530553A Pending JP2010504994A (ja) 2006-09-28 2007-09-25 2−メチレン−(20s,25s)−19,27−ジノル−(22e)−ビタミンd類縁体

Country Status (9)

Country Link
US (1) US8114859B2 (cg-RX-API-DMAC7.html)
EP (1) EP2069296B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010504994A (cg-RX-API-DMAC7.html)
AT (1) ATE552238T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007300211A1 (cg-RX-API-DMAC7.html)
CA (1) CA2662864A1 (cg-RX-API-DMAC7.html)
MX (1) MX2009002944A (cg-RX-API-DMAC7.html)
NZ (1) NZ575159A (cg-RX-API-DMAC7.html)
WO (1) WO2008039751A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399439B2 (en) 2008-07-10 2013-03-19 Wisconsin Alumni Research Foundation 2-methylene-19,26-dinor-(20S,22E,25R)-vitamin D analogs
MX2012003883A (es) * 2009-10-02 2012-06-27 Wisconsin Alumni Res Found Analogos de (20s,22e)-2-metileno-19-nor-22-ene-1a,25-dihidroxovita mina d3.
CA2824870C (en) * 2011-06-14 2018-08-14 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-19-nor-vitamin d analogs and their uses
US9545302B2 (en) 2013-11-20 2017-01-17 Dermagenesis Llc Skin printing and auto-grafting
US20150140058A1 (en) * 2013-11-20 2015-05-21 Dermagenesis Llc Skin printing and auto-grafting

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486333A (en) * 1981-04-10 1984-12-04 Felix Sebba Preparation of biliquid foam compositions
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
DE69400495T2 (de) * 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
PT2915534T (pt) * 1999-04-23 2018-06-20 Leo Pharma As Composição farmacêutica para aplicação dérmica para uso no tratamento da psoríase compreendendo vitamina d e um corticosteroide
AU2001265272B2 (en) * 2000-05-31 2006-08-17 Wisconsin Alumni Research Foundation 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
JP2004505515A (ja) 2000-07-21 2004-02-19 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ ユーザプロファイルを決定する方法及びシステム
BR0113703A (pt) * 2000-09-08 2003-07-22 Wisconsin Alumni Researcg Foun Compostos e métodos de tratamento de psorìase, leucemia, câncer do cólon, do seio ou da próstata, osteodistrofia renal, de doenças auto-imune, inflamatória e de condição de pele
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
US20050009792A1 (en) 2003-07-08 2005-01-13 Deluca Hector F. (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses
CA2544502A1 (en) 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment
CA2588406A1 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-.alpha.-methyl and 2-.beta.-methyl analogs of 19,26,27-trinor-(20s-1.alpha.-hydroxyvitamin d3 and their uses
US7528122B2 (en) 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
WO2008035207A2 (en) * 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof

Similar Documents

Publication Publication Date Title
JP2010505739A5 (cg-RX-API-DMAC7.html)
JP2010504995A5 (cg-RX-API-DMAC7.html)
JP2009532458A5 (cg-RX-API-DMAC7.html)
JP2008520689A5 (cg-RX-API-DMAC7.html)
JP2008520703A5 (cg-RX-API-DMAC7.html)
JP2005529878A5 (cg-RX-API-DMAC7.html)
Boulet et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma
JP2010504994A5 (cg-RX-API-DMAC7.html)
CA2420026A1 (en) 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
JP2008520691A5 (cg-RX-API-DMAC7.html)
JP2008520705A5 (cg-RX-API-DMAC7.html)
Turner et al. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis.
CA2588410A1 (en) 2-methylene-19-nor-1.alpha.-hydroxy-17-ene-homopregnacalciferol and its uses
CA2588415A1 (en) 2-methylene-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and its uses
JP2011527699A5 (cg-RX-API-DMAC7.html)
JP2011527695A5 (cg-RX-API-DMAC7.html)
JP2008520704A5 (cg-RX-API-DMAC7.html)
JP2009533483A5 (cg-RX-API-DMAC7.html)
JP2011527696A5 (cg-RX-API-DMAC7.html)
JP2008520690A5 (cg-RX-API-DMAC7.html)
CA2531505A1 (en) (20s)-1.alpha.-hydroxy-2-methylene-19-nor-vitamin d3 and its uses
JP2008530110A5 (cg-RX-API-DMAC7.html)
JP2008520709A5 (cg-RX-API-DMAC7.html)
EP3595649B1 (en) 5-((2r,4ar,10br)-9-ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)1-methyl-1h-pyridin-2-one for use in the treatment of idiopathic pulmonary fibrosis
JP2004521951A5 (cg-RX-API-DMAC7.html)